GUD.TO - Knight Therapeutics Inc.

Toronto - Toronto Delayed Price. Currency in CAD
7.42
-0.01 (-0.13%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous close7.43
Open7.42
Bid7.41 x 0
Ask7.42 x 0
Day's range7.37 - 7.46
52-week range7.10 - 8.88
Volume127,331
Avg. volume241,627
Market cap1.006B
Beta (5Y monthly)0.68
PE ratio (TTM)49.14
EPS (TTM)0.15
Earnings date11-Nov-2019
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est10.16
  • GlobeNewswire

    Quebec, New Brunswick, Newfoundland, Nova Scotia and Manitoba join Alberta, Saskatchewan, in adding Knight’s PROBUPHINE® to their provincial drug plans in the fight against the opioid crisis

    PROBUPHINE® is also listed for reimbursement through the Non-Insured Health Benefit (NIHB) and Veteran Affairs Canada drug plansPROBUPHINE® is the first and only buprenorphine.

  • GlobeNewswire

    Knight Partners with Debiopharm for the Commercialization of Trelstar® in Canada

    Knight expects to take over commercial activities from Debiopharm’s current partner Allergan and begin recording revenues in early 2020. Previously, Trelstar® was successfully launched and commercialized in Canada by Paladin Labs Inc. between 2006 to 2014.

  • GlobeNewswire

    Knight to Present at the J.P. Morgan Healthcare Conference in San Francisco

    MONTREAL, Jan. 07, 2020 -- Knight Therapeutics Inc. (TSX: GUD) ("Knight") a leading pan-American (ex-USA) specialty pharmaceutical company, announced today that Samira Sakhia,.

  • GlobeNewswire

    Knight Therapeutics Announces Submission to B3 S.A. For Unified Tender Offer

    Knight Therapeutics Inc. (GUD.TO) and its wholly owned subsidiary 1178991 CANADA INC. ("Knight" or “Offeror”) today announced that, further to its acquisition of a controlling interest (the “Transfer of Control”) in Biotoscana Investments S.A. (“GBT” or “Company”), it has submitted to B3 S.A. – Brasil, Bolsa, Balcão (“B3”) the authorization request to carry out a Unified Tender Offer (as defined below) for the acquisition of all outstanding Brazilian Depositary Receipts – BDRs of GBT (“BDRs”). The Unified Tender Offer aims at (i) fulfilling Knight’s statutory obligation to conduct a public offer for the acquisition of the outstanding BDRs following the Transfer of Control (“Tag Along Tender Offer”); and (ii) the voluntary discontinuity of the BDRs Program of the Company (“Discontinuity of the BDR Program”).

  • GlobeNewswire

    Knight Therapeutics Announces Closing of Previously Announced Acquisition of Grupo Biotoscana

    As announced on October 21, 2019, Knight paid BRL 10.96 per share or BRL 596 million (C$187 million(1)) (“Purchase Price”) in cash consideration for this controlling interest in GBT. Knight now controls the board of directors of GBT.

  • GlobeNewswire

    Knight and TherapeuticsMD Announce Filing of New Drug Submission for Bijuva® in Canada

    Knight Therapeutics Inc. (GUD.TO) (“Knight”) and TherapeuticsMD, Inc. (TXMD) (“TherapeuticsMD”) announced today that Knight's New Drug Submission (NDS) for Bijuva® has been accepted for review by Health Canada. Bijuva is a bio-identical* hormone therapy combination of estradiol and progesterone in a single, daily oral capsule intended for the treatment of moderate to severe vasomotor symptoms associated with menopause in women with intact uteri.

  • GlobeNewswire

    Profound Medical Announces Health Canada Approval of TULSA-PRO®

    Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, today announced Health Canada approval of the TULSA-PRO® system for the ablation of low to intermediate risk organ-confined prostate cancer. TULSA-PRO® is a transurethral prostate tissue ablation system that combines real-time Magnetic Resonance Imaging (“MRI”) with robotically-driven directional thermal ultrasound and closed-loop temperature feedback control software to deliver predictable physician prescribed ablation of whole-gland or partial prostate tissue.

  • GlobeNewswire

    GUD Medison Resolved

    Knight and Medison have entered into a definitive agreement pursuant to which Knight will sell to the Medison group all of Knight’s shares in Medison, reflecting approximately 28.3% of the share capital of Medison, in consideration for CA$77,000,000 payable in cash. In addition, the parties agreed to release each other from all claims and withdraw all legal proceedings initiated by both parties.

  • GlobeNewswire

    Knight Therapeutics Reports Third Quarter 2019 Results

    MONTREAL, Nov. 12, 2019 -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a Canadian specialty pharmaceutical company, today reported financial results for its third quarter.

  • GlobeNewswire

    Notice of Knight Therapeutics' Third Quarter 2019 Results Conference Call

    MONTREAL, Nov. 05, 2019 -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, will release its third quarter 2019 financial.

  • GlobeNewswire

    Knight and TherapeuticsMD Announce Filing of New Drug Submission for Joyesta™ in Canada

    Knight Therapeutics Inc. (GUD.TO) (“Knight”) and TherapeuticsMD, Inc. (TXMD) (“TherapeuticsMD”) announced today that Knight's New Drug Submission (NDS) for Joyesta™ has been accepted for review by Health Canada. Joyesta, licensed from TherapeuticsMD, is an applicator-free estradiol softgel vaginal capsule for the treatment of postmenopausal symptoms of vulvar and vaginal atrophy due to estrogen deficiency. Joyesta is marketed as IMVEXXY® (estradiol vaginal inserts) by TherapeuticsMD in the U.S., for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.

  • GlobeNewswire

    Knight Therapeutics and SIFI S.p.A. Announce Approval of NETILDEX™ in Canada

    Knight Therapeutics Inc. (GUD.TO) (“Knight”), a leading Canadian specialty pharmaceutical company, and SIFI S.p.A. (“SIFI”), a prominent Italian Eye Care company, today announced that Health Canada has approved NETILDEX® for the treatment of inflammatory ocular conditions of the anterior segment of the eye following cataract surgery where adjunct topical therapy to reduce the risk of bacterial infection is appropriate.  Knight and SIFI entered into an exclusive Canadian agreement NETILDEX® in August 2016. “We are excited about the approval of NETILDEX® in Canada, providing patients with a new antibiotic with a well-established corticosteroid” said Jonathan Ross Goodman, Chief Executive Officer of Knight.

  • GlobeNewswire

    Knight Therapeutics to Acquire Grupo Biotoscana, Establishing a Latin American Growth Platform

    Knight Therapeutics Inc. (GUD.TO) ("Knight") today announced that it has entered into a definitive agreement under which Knight will acquire a 51.21% interest in Biotoscana Investments S.A. (B3:GBIO33) (“GBT” or “Grupo Biotoscana”) from a controlling shareholder group that includes Advent International and Essex Woodlands, among others, for BRL 10.96 per share. This implies a 22.2% premium to GBT’s 30-day volume weighted average share price as of October 18, 2019.

  • GlobeNewswire

    Knight Therapeutics Reports Second Quarter 2019 Results

    MONTREAL, Aug. 08, 2019 -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a Canadian specialty pharmaceutical company, today reported financial results for its second quarter.

  • GlobeNewswire

    Knight Announces Early Warning Filing Regarding Disposition of Shares of Crescita

    This press release is being disseminated by Knight Therapeutics Inc. ("Knight") (GUD.TO), a specialty pharmaceutical company, as required by National Instrument 62-103 - The Early Warning System and Related Take Over Bid and Insider Reporting Issues regarding the disposition of securities of Crescita Therapeutics Inc. ("Crescita"). The Crescita Shares sold were previously acquired by Knight at an average cost of $0.60 per share. Prior to the dispositions, Knight owned 2,834,689 Crescita Shares representing approximately 13.5% of the outstanding Crescita Shares and 396,000 common share purchase warrants of Crescita (the “Warrants”).

  • GlobeNewswire

    Knight Therapeutics and pan-Canadian Pharmaceutical Alliance (pCPA) Reach Agreement for PROBUPHINE® for Opioid Dependence

    PROBUPHINE® is the first and only buprenorphine implant approved in Canada for the long-term maintenance management of opioid dependence in patients clinically stabilized on no more than 8 mg of sublingual buprenorphine in combination with counseling and psychosocial support1. MONTREAL, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (GUD.TO) ("Knight"), a leading Canadian specialty pharmaceutical company, announced today that it has reached an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for a Letter of Intent (LOI) regarding  PROBUPHINE® (buprenorphine hydrochloride subdermal implant).

  • GlobeNewswire

    Notice of Knight Therapeutics' Second Quarter 2019 Results Conference Call

    MONTREAL, Aug. 01, 2019 -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, will release its second quarter 2019 financial.

  • Is Knight Therapeutics Inc. (TSE:GUD) Potentially Underrated?
    Simply Wall St.

    Is Knight Therapeutics Inc. (TSE:GUD) Potentially Underrated?

    Knight Therapeutics Inc. (TSE:GUD) is a stock with outstanding fundamental characteristics. When we build an...

  • GlobeNewswire

    Knight Therapeutics Announces Health Canada Has Approved NERLYNX ® for Early-Stage Breast Cancer

    MONTREAL, July 16, 2019 -- Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, announced today that Health Canada has approved.

  • GlobeNewswire

    Knight Announces Normal Course Issuer Bid

    Knight Therapeutics Inc. (GUD.TO) (“Knight” or the “Company ”), a leading Canadian specialty pharmaceutical company, announced today acceptance by the Toronto Stock Exchange (the "TSX") of the Company's Notice of Intention to Make a Normal Course Issuer Bid ("NCIB").  Pursuant to the NCIB, the Company proposes to purchase, from time to time over the next 12 months, if considered advisable, up to 12,053,693 common shares of the Company, being approximately 10% of its public float of 120,536,931 common shares, as of July 2, 2019. As of July 2, 2019, there were a total of 142,868,687 common shares issued and outstanding.